Prosecution Insights
Last updated: August 07, 2026

Jiangsu Hansoh Pharmaceutical Group Co. Ltd.

8 pending office actions • 4 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
4
Non-Final OAs
3
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Due ≤ 60 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
6
Medium (75%)
2
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (38%)
§102 only2 (25%)
§112 only1 (12%)
Double-patenting only1 (12%)
Double-patenting + other1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
88% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
12% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
JACKSON, SHAWQUIA 1 77.9% -3.4%
RZECZYCKI, PHILLIP MATTHEW 1 62.7% +39.6%
REDWOOD, CHRISTOPHER EVAN 1
SEAMAN, D MARGARET M 1 76.6% +8.0%
HUI, SAN MING R 1 59.3% +19.9%
PECKHAM, RICHARD GRANT 1 67.2% +37.0%
TOWNSLEY, SARA ELIZABETH 1 25.1% +48.8%
PUTTLITZ, KARL J 1 69.1% +18.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18017666 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF TOWNSLEY, SARA ELIZABETH 71d

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17596239 ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF PUTTLITZ, KARL J 34d
18036730 CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM PECKHAM, RICHARD GRANT 62d
18017666 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF TOWNSLEY, SARA ELIZABETH 71d
18685882 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF RZECZYCKI, PHILLIP MATTHEW
18254623 SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF HUI, SAN MING R

Top Art Units

Art UnitApps
1625 2
1629 2
1627 2
1646 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18723812 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JACKSON, SHAWQUIA §102 Non-Final OA Pending Jun 24, 2024
18685882 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF RZECZYCKI, PHILLIP MATTHEW 1625 §102§103§112DP Non-Final OA Pending Feb 22, 2024
18293637 CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF REDWOOD, CHRISTOPHER EVAN 1629 §103 Non-Final OA Pending Jan 30, 2024
18551180 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SEAMAN, D MARGARET M 1625 §102 Non-Final OA Pending Sep 18, 2023
18254623 SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF HUI, SAN MING R 1627 DP Final Rejection Pending May 26, 2023
18036730 CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM PECKHAM, RICHARD GRANT 1627 §112 Non-Final OA 62d Pending May 12, 2023
18017666 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF TOWNSLEY, SARA ELIZABETH 1629 §103 Final Rejection 71d Pending Jan 23, 2023
17596239 ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF PUTTLITZ, KARL J 1646 §103 Final Rejection 34d Pending Dec 06, 2021

Managing Jiangsu Hansoh Pharmaceutical Group Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month